AHFS Drug Information April 2025 Update

This update contains 9 new monographs and 44 revised monographs.

New monographs: Concizumab; Cosibelimab; Datopotamab Deruxtecan; Elagolix Sodium, Estradiol, and Norethindrone Acetate; Ensartinib Hydrochloride; Suzetrigine; Treosulfan; Vanzacaftor Calcium, Tezacaftor, and Deutivacaftor; Zenocutuzumab.

Revised monographs: Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl; Avacincaptad Pegol Sodium; Belumosudil Mesylate; Belzutifan; Brodalumab; cefTRIAXone Sodium; Certolizumab Pegol; Darunavir Ethanolate, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Fumarate; Dolutegravir Sodium; Dolutegravir Sodium and Rilpivirine Hydrochloride; Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Fumarate; Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate; Emtricitabine and Tenofovir Disoproxil Fumarate; Evolocumab; fentaNYL, fentaNYL Citrate; Fostemsavir Tromethamine; Glatiramer Acetate; Ibalizumab; Ibuprofen, Ibuprofen Lysine; lamiVUDine; Lonafarnib; Lopinavir and Ritonavir; Lurasidone Hydrochloride; Maraviroc; Methotrexate; Mirtazapine; Molnupiravir; Nabumetone; Nemolizumab; Pimavanserin Tartrate; Raltegravir Potassium; Remdesivir; Remifentanil Hydrochloride; Ribavirin; Sparsentan; Sulbactam Sodium and Durlobactam Sodium; Tazemetostat Hydrobromide; Teclistamab; Teduglutide; Tenofovir Alafenamide Fumarate; Tenofovir Disoproxil Fumarate; Toripalimab; Vilobelimab; Zidovudine.